Long-term GH treatment of GH-deficient adults: Comparison between one and two daily injections

Journal of Endocrinological Investigation

Volumn 29, Issue 11, 2006, Pages 950-956

  Höybye, Charlotte ^a   Rudling, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adult GHD; GH treatment; Lipid profile; One or two doses day

Indexed keywords

CARBOHYDRATE; CHOLESTEROL; ESTROGEN; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TESTOSTERONE; THYROXINE; TRIACYLGLYCEROL; LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; BONE DENSITY; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPHYSIS DISEASE; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MALE; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADIPOSE TISSUE; BLOOD; CIRCADIAN RHYTHM; DRUG ADMINISTRATION; DRUG EFFECT; HISTOLOGY; MIDDLE AGED;

ADIPOSE TISSUE; ADULT; AGED; BODY COMPOSITION; CHOLESTEROL; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 33846968504     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349206     Document Type: Article

References (47)

1. Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest 1968, 47: 2079-90.
2. Plotnick LP, Thompson RG, Kowarski A, de Lacerda L, Migeon CJ, Blizzard RM. Circadian variation of integrated concentration of growth hormone in children and adults. J Clin Endocrinol Metab 1975, 40: 240-7.
3. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998, 19: 717-97.
4. Edén S, Jansson JO, Oscarsson J. Sexual dimorphism of growth hormone secretion. In: Isaksson O, Binder C, Hall K, Hokfelt B eds. Growth hormone-basic and clinical aspects. Amsterdam: Elsevier Science Publishers BV 1987, 129-53.
5. Jansson JO, Albertsson-Wikland K, Eden S, Thorngren KG, Isaksson O. Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol Scand 1982, 114:261-5.
6. Albertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand 1986, 75: 89-97.
7. Christiansen JS, Orskov H, Binder C, Kastrup KW. Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children. Acta Endocrinol (Copenh) 1983, 102: 6-10.
8. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998, 83: 382-95.
9. Kastrup KW, Christiansen JS, Andersen JK, Orskov H. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh) 1983, 104: 148-52.
10. Salomon F, Cuneo RC. Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1797-803.
11. Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989, 1: 1221-5.
12. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002, 87: 2121-7.
13. Beshyah SA, Henderson A, Niththyananthan R, et al. The effects of short- and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995, 80: 356-63.
14. Jorgensen JO, Moller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990, 70: 207-14.
15. Jorgensen JO, Moller N, Lauritzen T, Christiansen JS. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 1990, 70: 1616-23.
16. Tauber M, De Bouet Du Portal H, Sallerin-Caute B, Rochiccioli P, Bastide R. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 1993, 76: 1135-9.
17. Laursen T, Jorgensen JO, Christiansen JS. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clin Endocrinol (Oxf) 1994, 41: 337-43.
18. Laursen T, Gravholt CH, Heickendorff L, et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 2001, 86: 1222-8.
19. Johansson JO, Wiren L, Oscarsson J, Bengtsson BA, Johannsson G. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections. Growth Horm IGF Res 2003, 13: 306-15.
20. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000, 43: 1507-11.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
22. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47: 1643-9.
23. Tothill P, Avenell A, Love J, Reid DM. Comparisons between Hologic, Lunar and Norland dual-energy X-ray absorptiometers and other techniques used for whole-body soft tissue measurements. Eur J Clin Nut 1994, 48: 781-94.
24. Anonymous Assessment of Fracture Risk and it's application to screening for postmenopausal osteoporosis. WHO Technical Report series, Geneva, 1994, p. 843.
25. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991, 124: 620-9.
26. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999, 84: 2013-9.
27. Povoa G, Roovete A, Hall, K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984, 107: 563-70.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
29. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 2006, 36: 98-104.
30. Axelson M, Aly A, Sjovall J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988, 239: 324-8.
31. Axelson M, Bjorkhem I, Reihner E, Einarsson K. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 1991, 284: 216-8.
32. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003, 44: 859-66.
33. Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 1996, 24: 123-6.
34. Oscarsson J, Johannsson G, Johansson JO, Lundberg PA, Lindstedt G, Bengtsson BA. Diurnal variation in serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Clin Endocrinol (Oxf) 1997, 46: 63-8.
35. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993, 13: 296-301.
36. Hwu CM, Kwok CF, Lai TY, et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997, 82: 3285-92.
37. Johannsson G, Oscarsson J, Rosen T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995, 15: 2142-50.
38. Oscarsson J, Ottosson M, Johansson JO, et al. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. Metabolism 1996, 45: 370-7.
39. Fernholm R, Bramnert M, Hägg E, et al. Growth hormone replacement therapy improves body composition in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000, 85: 4104-12.
40. Benbassat CA, Wasserman M, Laron Z. Changes in bone mineral density after discontinuation and early reinstitution of growth hormone (GH) in patients with childhood-onset GH deficiency. Growth Horm IGF Res 1999, 9: 290-5.
41. Olivecrona H, Ericsson S, Angelin B. Growth hormone treatment does not alter biliary lipid metabolism in healthy adult men. J Clin Endocrinol Metab 1995, 80: 1113-7.
42. Lind S, Rudling M, Ericsson S, et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol 2004, 24: 349-56.
43. Leonsson M, Oscarsson J, Bosaeus I, et al. Growth hormone (GH) therapy in GH-deficient adults influences the response to a dietary load of cholesterol and saturated fat in terms of cholesterol synthesis, but not serum low density lipoprotein cholesterol levels. J Clin Endocrinol Metab 1999, 84: 1296-303.
44. Rudling M, Parini P, Angelin B. Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat. J Clin Invest 1997, 99: 2239-45.
45. Parini P, Angelin B, Rudling M. Cholesterol and lipoprotein metabolism in aging: reversal of hypercholesterolemia by growth hormone treatment in old rats. Arterioscler Thromb Vasc Biol 1999, 19: 832-9.
46. Rudling M, Angelin B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J 2001, 15: 1350-6.
47. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992, 89: 6983-7.